Table 6.

Sensitivity analysis for secondary analysis.

PPI exposure	HR (95% CI)
	Crude HR	Model 1	Model 2
Lag 180 d
Unexposed	Reference	Reference	Reference
Exposed	1.45 (1.42, 1.48)	1.32 (1.30, 1.35)	1.27 (1.24, 1.29)
p value	< 0.001	< 0.001	< 0.001
Lag 365 d
Unexposed	Reference	Reference	Reference
Exposed	1.38 (1.35, 1.41)	1.27 (1.25, 1.30)	1.21 (1.19, 1.24)
p value	< 0.001	< 0.001	< 0.001
Lag 730 d
Unexposed	Reference	Reference	Reference
Exposed	1.27 (1.24, 1.30)	1.18 (1.15, 1.20)	1.12 (1.09, 1.15)
p value	< 0.001	0.868	< 0.001
Diagnosis twice
Unexposed	Reference	Reference	Reference
Exposed	1.62 (1.58, 1.66)	1.41 (1.38, 1.45)	1.35 (1.31, 1.38)
p value	< 0.001	< 0.001	< 0.001

Model 1 was adjusted for age, sex, income level, number of gastroendoscopies and visits, comorbidities (gastritis, gastric cancer, gastrointestinal hemorrhage, hypertension, dyslipidemia, insomnia, vertigo, hearing loss) and Charlson Comorbidity Index score in the 365 days before the index date. Model 2 was adjusted for age, sex, income level, number of gastroendoscopies and visits, comorbidities (gastritis, gastric cancer, gastrointestinal hemorrhage, hypertension, dyslipidemia, insomnia, vertigo, hearing loss), and medications (H2RAs, antidepressants, benzodiazepines, calcium channel blockers, Ginkgo biloba, steroids), and Charlson Comorbidity Index score in the 365 days before the index date. CI: confidence interval; H2RA: H2 receptor antagonist; HR: hazard ratio; PPI: proton pump inhibitor.